Literature DB >> 26005525

Design and Validation of FRESH, a Drug Discovery Paradigm Resting on Robust Chemical Synthesis.

Qi Shi1, Thomas M Kaiser1, Zackery W Dentmon1, Mariangela Ceruso2, Daniela Vullo2, Claudiu T Supuran2, James P Snyder1.   

Abstract

A method capable of identifying novel synthetic targets for small molecule lead optimization has been developed. The FRESH (FRagment-based Exploitation of modular Synthesis by vHTS) approach relies on a multistep synthetic route to a target series of compounds devised by a close collaboration between synthetic and computational chemists. It combines compound library generation, quantitative structure-acitvity relationship construction, fragment processing, virtual high throughput screening and display of results within the Pipeline Pilot framework. Outcomes enumerate tailored selection of novel synthetic targets with improved potency and optimized physical properties for an emerging compound series. To validate the application of FRESH, three retrospective case studies have been performed to pinpoint reported potent analogues. One prospective case study was performed to demonstrate that FRESH is able to capture additional potent analogues.

Keywords:  ADME; FRESH; Pipeline Pilot; QSAR; lead optimization; virtual HTS

Year:  2015        PMID: 26005525      PMCID: PMC4434458          DOI: 10.1021/acsmedchemlett.5b00062

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  23 in total

1.  Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency.

Authors:  Fabio Pacchiano; Mayank Aggarwal; Balendu Sankara Avvaru; Arthur H Robbins; Andrea Scozzafava; Robert McKenna; Claudiu T Supuran
Journal:  Chem Commun (Camb)       Date:  2010-10-05       Impact factor: 6.222

Review 2.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators.

Authors:  Claudiu T Supuran
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

3.  A novel two-step QSAR modeling work flow to predict selectivity and activity of HDAC inhibitors.

Authors:  Lingling Zhao; Yuhong Xiang; Jinglin Song; Zhuoyong Zhang
Journal:  Bioorg Med Chem Lett       Date:  2013-01-03       Impact factor: 2.823

4.  Regulation of breast cancer cell chemotaxis by the phosphoinositide 3-kinase p110delta.

Authors:  Carol Sawyer; Justin Sturge; Dorothy C Bennett; Michael J O'Hare; William E Allen; Jennifer Bain; Gareth E Jones; Bart Vanhaesebroeck
Journal:  Cancer Res       Date:  2003-04-01       Impact factor: 12.701

Review 5.  Histone deacetylases (HDACs): characterization of the classical HDAC family.

Authors:  Annemieke J M de Ruijter; Albert H van Gennip; Huib N Caron; Stephan Kemp; André B P van Kuilenburg
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

6.  Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.

Authors:  Okseon Kim; Yujeong Jeong; Hyunseung Lee; Sun-Sun Hong; Sungwoo Hong
Journal:  J Med Chem       Date:  2011-03-09       Impact factor: 7.446

7.  Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation.

Authors:  Hao Tang; Xiang S Wang; Xi-Ping Huang; Bryan L Roth; Kyle V Butler; Alan P Kozikowski; Mira Jung; Alexander Tropsha
Journal:  J Chem Inf Model       Date:  2009-02       Impact factor: 4.956

Review 8.  Efficient drug lead discovery and optimization.

Authors:  William L Jorgensen
Journal:  Acc Chem Res       Date:  2009-06-16       Impact factor: 22.384

9.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA.

Authors:  Keith B Glaser; Junling Li; Michael J Staver; Ru-Qi Wei; Daniel H Albert; Steven K Davidsen
Journal:  Biochem Biophys Res Commun       Date:  2003-10-17       Impact factor: 3.575

Review 10.  Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.

Authors:  Akintunde Akinleye; Parthu Avvaru; Muhammad Furqan; Yongping Song; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-11-22       Impact factor: 17.388

View more
  3 in total

1.  Accelerated Discovery of Potent Fusion Inhibitors for Respiratory Syncytial Virus.

Authors:  Nicole Pribut; Thomas M Kaiser; Robert J Wilson; Edgars Jecs; Zackery W Dentmon; Stephen C Pelly; Savita Sharma; Perry W Bartsch; Pieter B Burger; Soyon S Hwang; Thalia Le; Julien Sourimant; Jeong-Joong Yoon; Richard K Plemper; Dennis C Liotta
Journal:  ACS Infect Dis       Date:  2020-04-20       Impact factor: 5.084

2.  Development of CXCR4 modulators by virtual HTS of a novel amide-sulfamide compound library.

Authors:  Renren Bai; Qi Shi; Zhongxing Liang; Younghyoun Yoon; Yiran Han; Amber Feng; Shuangping Liu; Yoonhyeun Oum; C Chris Yun; Hyunsuk Shim
Journal:  Eur J Med Chem       Date:  2016-11-24       Impact factor: 6.514

3.  Accelerated Discovery of Novel Ponatinib Analogs with Improved Properties for the Treatment of Parkinson's Disease.

Authors:  Thomas M Kaiser; Zackery W Dentmon; Christopher E Dalloul; Savita K Sharma; Dennis C Liotta
Journal:  ACS Med Chem Lett       Date:  2020-03-12       Impact factor: 4.345

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.